{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:27:46Z","timestamp":1786998466001,"version":"build-2736575974"},"reference-count":168,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis US LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ymgme.2024.108590","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T19:08:40Z","timestamp":1728673720000},"page":"108590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pompe disease: Unmet needs and emerging therapies"],"prefix":"10.1016","volume":"143","author":[{"given":"Kelly A.","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allyson L.","family":"Anding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio S.","family":"Tomassy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth I.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Pablo","family":"Sardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ymgme.2024.108590_bb0005","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ncl.2014.04.010","article-title":"Pompe disease: literature review and case series","volume":"32","author":"Dasouki","year":"2014","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.ymgme.2024.108590_bb0010","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","article-title":"Pompe disease: from basic science to therapy","volume":"15","author":"Kohler","year":"2018","journal-title":"Neurotherapeutics"},{"issue":"12","key":"10.1016\/j.ymgme.2024.108590_bb0015","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/labinvest.3700484","article-title":"Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease","volume":"86","author":"Thurberg","year":"2006","journal-title":"Lab. Invest."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108590_bb0020","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108590_bb0025","doi-asserted-by":"crossref","first-page":"e1116","DOI":"10.1542\/peds.2008-3667","article-title":"Pompe disease in infants: improving the prognosis by newborn screening and early treatment","volume":"124","author":"Chien","year":"2009","journal-title":"Pediatrics"},{"issue":"13","key":"10.1016\/j.ymgme.2024.108590_bb0030","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2019.04.70","article-title":"Long-term outcome and unmet needs in infantile-onset Pompe disease","volume":"7","author":"Hahn","year":"2019","journal-title":"Annals of Translational Medicine."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108590_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-7-35","article-title":"A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations","volume":"7","author":"Herzog","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0040","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid \u03b1-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ymgme.2024.108590_bb0045","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alfa prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr. Res."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108590_bb0050","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pedneo.2013.03.009","article-title":"Pompe disease: early diagnosis and early treatment make a difference","volume":"54","author":"Chien","year":"2013","journal-title":"Pediatr. Neonatol."},{"issue":"174\u2013180","key":"10.1016\/j.ymgme.2024.108590_bb0055","article-title":"Very early treatment for infantile-onset Pompe disease contributes to better outcomes","volume":"169","author":"Yang","year":"2016","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2024.108590_bb0060","author":"ClinicalTrials.gov"},{"issue":"23","key":"10.1016\/j.ymgme.2024.108590_bb0065","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2200587","article-title":"In utero enzyme-replacement therapy for infantile-onset Pompe\u2019s disease","volume":"387","author":"Cohen","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2022.10.010","article-title":"Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label mini-COMET study: the 6-month primary analysis report","volume":"25","author":"Kishnani","year":"2023","journal-title":"Genet. Med."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108590_bb0075","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/jimd.12268","article-title":"Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long-term clinical outcome of classic infantile Pompe patients","volume":"43","author":"Poelman","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108590_bb0080","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S2352-4642(21)00308-4","article-title":"Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium","volume":"6","author":"Ditters","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"issue":"1","key":"10.1016\/j.ymgme.2024.108590_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-8-49","article-title":"Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study","volume":"8","author":"G\u00fcng\u00f6r","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"issue":"15","key":"10.1016\/j.ymgme.2024.108590_bb0090","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease","volume":"362","author":"Van der Ploeg","year":"2010","journal-title":"New England Journal of Medicine."},{"key":"10.1016\/j.ymgme.2024.108590_bb0095","series-title":"Summary of Product Characteristics [Myozyme]","volume":"2022","author":"Genzyme","year":"2022"},{"issue":"9","key":"10.1016\/j.ymgme.2024.108590_bb0100","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16383","article-title":"Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe consortium recommendation update 2024","volume":"31","author":"Schoser","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ymgme.2024.108590_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-8-90","article-title":"Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy","volume":"8","author":"Prater","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2024.108590_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgmr.2020.100591","article-title":"Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: evidence from real-world experiences","volume":"23","author":"Chien","year":"2020","journal-title":"Molecular Genetics and Metabolism Reports."},{"issue":"13","key":"10.1016\/j.ymgme.2024.108590_bb0115","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2019.05.27","article-title":"Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review","volume":"7","author":"Desai","year":"2019","journal-title":"Annals of Translational Medicine."},{"key":"10.1016\/j.ymgme.2024.108590_bb0120","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1007\/s00415-021-10409-9","article-title":"STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa","volume":"268","author":"Gutschmidt","year":"2021","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0125","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ymgme.2017.04.014","article-title":"Cognitive and academic outcomes in long-term survivors of infantile-onset Pompe disease: a longitudinal follow-up","volume":"121","author":"Spiridigliozzi","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108590_bb0130","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2016.12.004","article-title":"The emerging phenotype of late-onset Pompe disease: a systematic literature review","volume":"120","author":"Chan","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108590_bb0135","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00687878","article-title":"Pompe\u2019s disease: an inborn lysosomal disorder with storage of glycogen: a study of brain and striated muscle","volume":"23","author":"Martin","year":"1973","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ymgme.2024.108590_bb0140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/8904_2015_426","article-title":"Postmortem findings and clinical correlates in individuals with infantile-onset Pompe disease","volume":"23","author":"Pena","year":"2015","journal-title":"JIMD Reports"},{"key":"10.1016\/j.ymgme.2024.108590_bb0145","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/8904_2017_46","article-title":"Rapidly progressive white matter involvement in early childhood: the expanding phenotype of infantile onset Pompe?","volume":"39","author":"Broomfield","year":"2018","journal-title":"JIMD Reports"},{"issue":"6","key":"10.1016\/j.ymgme.2024.108590_bb0150","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/dmcn.13740","article-title":"Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain","volume":"60","author":"Ebbink","year":"2018","journal-title":"Developmental Medicine & Child Neurology."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0155","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ymgme.2017.10.005","article-title":"Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy","volume":"123","author":"McIntosh","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108590_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-018-0771-0","article-title":"Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy","volume":"13","author":"Parini","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"issue":"13","key":"10.1016\/j.ymgme.2024.108590_bb0165","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2019.04.49","article-title":"An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond","volume":"7","author":"Korlimarla","year":"2019","journal-title":"Annals of translational medicine."},{"key":"10.1016\/j.ymgme.2024.108590_bb0170","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.resp.2015.11.013","article-title":"Altered activation of the diaphragm in late-onset Pompe disease","volume":"222","author":"Smith","year":"2016","journal-title":"Respir. Physiol. Neurobiol."},{"issue":"9","key":"10.1016\/j.ymgme.2024.108590_bb0175","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gim.2012.44","article-title":"The emerging phenotype of long-term survivors with infantile Pompe disease","volume":"14","author":"Prater","year":"2012","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2024.108590_bb0180","article-title":"Severe CNS involvement in a subset of long-term treated children with infantile-onset Pompe disease","volume":"108119","author":"Kenney-Jung","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108590_bb0185","first-page":"1","article-title":"Long-term outcome of infantile onset pompe disease patients treated with enzyme replacement therapy-data from a german-austrian cohort","author":"Pfrimmer","year":"2024","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"1","key":"10.1016\/j.ymgme.2024.108590_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-8-182","article-title":"Phenotypical variation within 22 families with Pompe disease","volume":"8","author":"Wens","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108590_bb0195","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.nmd.2012.12.003","article-title":"Oropharyngeal dysphagia may occur in late-onset Pompe disease, implicating bulbar muscle involvement","volume":"23","author":"Hobson-Webb","year":"2013","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgme.2024.108590_bb0200","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10545-011-9404-7","article-title":"Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy","volume":"35","author":"van Gelder","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"issue":"8","key":"10.1016\/j.ymgme.2024.108590_bb0205","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.nmd.2016.05.018","article-title":"Progression from respiratory dysfunction to failure in late-onset Pompe disease","volume":"26","author":"Berger","year":"2016","journal-title":"Neuromuscul. Disord."},{"issue":"7","key":"10.1016\/j.ymgme.2024.108590_bb0210","doi-asserted-by":"crossref","first-page":"930","DOI":"10.4187\/respcare.03940","article-title":"Blunted hypercapnic respiratory drive response in subjects with late-onset Pompe disease","volume":"61","author":"De Vito","year":"2016","journal-title":"Respir. Care"},{"issue":"15","key":"10.1016\/j.ymgme.2024.108590_bb0215","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.3390\/jcm10153395","article-title":"New insights into gastrointestinal involvement in late-onset Pompe disease: lessons learned from bench and bedside","volume":"10","author":"Korlimarla","year":"2021","journal-title":"J. Clin. Med."},{"issue":"0","key":"10.1016\/j.ymgme.2024.108590_bb0220","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1540\/jsmr.57.8","article-title":"Glycogen accumulation in smooth muscle of a Pompe disease mouse model","volume":"57","author":"McCall","year":"2021","journal-title":"J. Smooth Muscle Res."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108590_bb0225","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/mus.22202","article-title":"Expanding the phenotype of late-onset Pompe disease: tongue weakness: a new clinical observation","volume":"44","author":"Dubrovsky","year":"2011","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.ymgme.2024.108590_bb0230","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1111\/ene.15330","article-title":"Macroglossia: a potentially severe complication of late-onset Pompe disease","volume":"29","author":"Dup\u00e9","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ymgme.2024.108590_bb0235","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/8904_2014_334","article-title":"Urge incontinence and gastrointestinal symptoms in adult patients with Pompe disease: a cross-sectional survey","volume":"17","author":"Karabul","year":"2014","journal-title":"JIMD Reports"},{"key":"10.1016\/j.ymgme.2024.108590_bb0240","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1540\/jsmr.54.100","article-title":"The impact of Pompe disease on smooth muscle: a review","volume":"54","author":"McCall","year":"2018","journal-title":"J. Smooth Muscle Res."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0245","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000338776","article-title":"Incontinence in late-onset Pompe disease: an underdiagnosed treatable condition","volume":"68","author":"Remiche","year":"2012","journal-title":"Eur. Neurol."},{"issue":"2\u20133","key":"10.1016\/j.ymgme.2024.108590_bb0250","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ymgme.2010.06.003","article-title":"Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients","volume":"101","author":"Bernstein","year":"2010","journal-title":"Mol. Genet. Metab."},{"issue":"7","key":"10.1016\/j.ymgme.2024.108590_bb0255","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/GIM.0b013e3182142966","article-title":"Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy","volume":"13","author":"Forsha","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2024.108590_bb0260","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/8904_2016_563","article-title":"Severe cardiomyopathy as the isolated presenting feature in an adult with late-onset Pompe disease: a case report","volume":"31","author":"Mori","year":"2017","journal-title":"JIMD Reports"},{"issue":"4","key":"10.1016\/j.ymgme.2024.108590_bb0265","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2796.2008.01966.x","article-title":"Cardiac involvement in adults with Pompe disease","volume":"264","author":"Soliman","year":"2008","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ymgme.2024.108590_bb0270","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00246-008-9267-3","article-title":"Cardiac remodeling after enzyme replacement therapy with acid \u03b1-glucosidase for infants with Pompe disease","volume":"29","author":"Levine","year":"2008","journal-title":"Pediatr. Cardiol."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108590_bb0275","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.gim.0000195896.04069.5f","article-title":"Electrocardiographic response to enzyme replacement therapy for Pompe disease","volume":"8","author":"Ansong","year":"2006","journal-title":"Genet. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0280","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3233\/JND-210728","article-title":"Late onset Pompe disease with novel mutations and atypical phenotypes","volume":"9","author":"Chawla","year":"2022","journal-title":"J Neuromuscul Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108590_bb0285","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/ane.13133","article-title":"Screening for late-onset Pompe disease in Poland","volume":"140","author":"Jastrz\u0119bska","year":"2019","journal-title":"Acta Neurol. Scand."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0290","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1017\/S0317167100016760","article-title":"Late onset Pompe disease mimicking rigid spine syndrome","volume":"41","author":"Panosyan","year":"2014","journal-title":"Can. J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0295","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.nmd.2009.11.006","article-title":"Rigid spine syndrome revealing late-onset Pompe disease","volume":"20","author":"Lafor\u00eat","year":"2010","journal-title":"Neuromuscul. Disord."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0300","first-page":"413","article-title":"Rigid spine syndrome in late-onset Pompe disease: a Case report and review of the literature","volume":"26","author":"Ng","year":"2021","journal-title":"Neurology Asia."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108590_bb0305","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bbamcr.2008.10.016","article-title":"Sorting of lysosomal proteins","volume":"1793","author":"Braulke","year":"2009","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular Cell Res."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108590_bb0310","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0021-9258(18)53985-5","article-title":"Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation","volume":"268","author":"Wisselaar","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.ymgme.2024.108590_bb0315","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1074\/jbc.M404008200","article-title":"Lysosomal acid \u03b1-glucosidase consists of four different peptides processed from a single chain precursor","volume":"280","author":"Moreland","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2024.108590_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100769","article-title":"Endolysosomal N-glycan processing is critical to attain the most active form of the enzyme acid alpha-glucosidase","volume":"296","author":"Selvan","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"14","key":"10.1016\/j.ymgme.2024.108590_bb0325","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1016\/S0021-9258(18)83136-2","article-title":"Ligand interactions of the cation-independent mannose 6-phosphate receptor: the stoichiometry of mannose 6-phosphate binding","volume":"264","author":"Tong","year":"1989","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108590_bb0330","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/j.bbrc.2017.12.101","article-title":"Four unreported types of glycans containing mannose-6-phosphate are heterogeneously attached at three sites (including newly found Asn 233) to recombinant human acid alpha-glucosidase that is the only approved treatment for Pompe disease","volume":"495","author":"Park","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108590_bb0335","first-page":"723","article-title":"Quantitation of Mr 46000 and Mr 300000 mannose 6-phosphate receptors in human cells and tissues","volume":"23","author":"Wenk","year":"1991","journal-title":"Biochem. Int."},{"key":"10.1016\/j.ymgme.2024.108590_bb0340","article-title":"Evaluating avalglucosidase alfa for the management of late-onset Pompe disease","volume":"1-8","author":"Angelini","year":"2024","journal-title":"Expert Rev. Neurother."},{"issue":"12","key":"10.1016\/j.ymgme.2024.108590_bb0345","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"The Lancet Neurology."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0350","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1124\/jpet.123.001593","article-title":"Increasing enzyme mannose-6-phosphate levels but not miglustat coadministration enhances the efficacy of enzyme replacement therapy in Pompe mice","volume":"387","author":"Anding","year":"2023","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108590_bb0355","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid \u03b1-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108590_bb0360","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1021\/bc1005416","article-title":"Strategies for neoglycan conjugation to human acid \u03b1-glucosidase","volume":"22","author":"Zhou","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ymgme.2024.108590_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108559","article-title":"Clinical insight meets scientific innovation to develop a next generation ERT for Pompe disease","author":"Kishnani","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108590_bb0370","article-title":"Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-na\u00efve adults with late-onset Pompe disease compared with alglucosidase alfa: meaningful change analyses from the phase 3 COMET trial","volume":"108121","author":"Toscano","year":"2023","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108590_bb0375","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1212\/WNL.0000000000200746","article-title":"Long-term safety and efficacy of avalglucosidase alfa in patients with late-onset Pompe disease","volume":"99","author":"Dimachkie","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2024.108590_bb0380","author":"European Medicines Agency"},{"issue":"12","key":"10.1016\/j.ymgme.2024.108590_bb0390","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","article-title":"Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial","volume":"20","author":"Schoser","year":"2021","journal-title":"The Lancet Neurology."},{"issue":"8","key":"10.1016\/j.ymgme.2024.108590_bb0400","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s40265-023-01886-5","article-title":"Cipaglucosidase alfa: first approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.ymgme.2024.108590_bb0405","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.125358","article-title":"Improved efficacy of a next-generation ERT in murine Pompe disease","volume":"4","author":"Xu","year":"2019","journal-title":"JCI Insight"},{"issue":"12","key":"10.1016\/j.ymgme.2024.108590_bb0410","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1016\/j.ymthe.2021.08.020","article-title":"Cell type-selective targeted delivery of a recombinant lysosomal enzyme for enzyme therapies","volume":"29","author":"Baik","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2024.108590_bb0415","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s10545-011-9285-9","article-title":"Biotherapeutic target or sink: analysis of the macrophage mannose receptor tissue distribution in murine models of lysosomal storage diseases","volume":"34","author":"Zhang","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108590_bb0420","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00109-017-1505-9","article-title":"Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease","volume":"95","author":"Yi","year":"2017","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.ymgme.2024.108590_bb0425","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.ymgme.2024.108590_bb0430","series-title":"Abstract 2.156: VAL-1221: A Phase II Candidate for Lafora Disease","author":"Armstrong","year":"2023"},{"issue":"1","key":"10.1016\/j.ymgme.2024.108590_bb0435","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neuron.2015.11.024","article-title":"Discovery of novel blood-brain barrier targets to enhance brain uptake of therapeutic antibodies","volume":"89","author":"Zuchero","year":"2016","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0440","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.chembiol.2023.09.008","article-title":"Bispecific antibody shuttles targeting CD98hc mediate efficient and long-lived brain delivery of IgGs","volume":"31","author":"Pornnoppadol","year":"2024","journal-title":"Cell. Chem. Biol."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0445","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymthe.2018.12.005","article-title":"Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic mucopolysaccharidosis II: a phase 1\/2 trial","volume":"27","author":"Okuyama","year":"2019","journal-title":"Mol Ther."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0450","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ymthe.2020.09.039","article-title":"A phase 2\/3 trial of pabinafusp alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II","volume":"29","author":"Okuyama","year":"2021","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108590_bb0455","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.ymthe.2018.02.032","article-title":"A blood-brain-barrier-penetrating anti-human transferrin receptor antibody fusion protein for neuronopathic mucopolysaccharidosis II","volume":"26","author":"Sonoda","year":"2018","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108590_bb0460","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14061240","article-title":"Treatment of neuronopathic mucopolysaccharidoses with blood-brain barrier-crossing enzymes: clinical application of receptor-mediated transcytosis","volume":"14","author":"Sonoda","year":"2022","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.ymgme.2024.108590_bb0470","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20211057","article-title":"Molecular architecture determines brain delivery of a transferrin receptor\u2013targeted lysosomal enzyme","volume":"219","author":"Arguello","year":"2022","journal-title":"J. Exp. Med."},{"issue":"545","key":"10.1016\/j.ymgme.2024.108590_bb0475","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay1359","article-title":"Brain delivery of therapeutic proteins using an fc fragment blood-brain barrier transport vehicle in mice and monkeys","volume":"12","author":"Kariolis","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"545","key":"10.1016\/j.ymgme.2024.108590_bb0480","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay1163","article-title":"Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice","volume":"12","author":"Ullman","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymgme.2024.108590_bb0485","author":"Burton"},{"key":"10.1016\/j.ymgme.2024.108590_bb0490","author":"Denali Therapeutics"},{"key":"10.1016\/j.ymgme.2024.108590_bb0495","author":"JCR Pharmaceuticals"},{"key":"10.1016\/j.ymgme.2024.108590_bb0500","series-title":"Anti-mouse-TfR-GAA Fusion Proteins for the Treatment of Pompe Disease Targeting the Central Nervous System and Peripheral Tissues. Poster LB-22. presented at: World Symposium","author":"George","year":"2023"},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.108062","article-title":"Anti-human-TfR-GAA efficiently clears CNS and muscle glycogen in a translatable hTfR-KI\/Pompe disease mouse model","volume":"141","author":"van der Flier","year":"2024","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108590_bb0510","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/s41467-023-37632-4","article-title":"Targeting neuronal lysosomal dysfunction caused by \u03b2-glucocerebrosidase deficiency with an enzyme-based brain shuttle construct","volume":"14","author":"Gehrlein","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymgme.2024.108590_bb0515","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.omtm.2022.09.010","article-title":"IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy","volume":"27","author":"Liang","year":"2022","journal-title":"Molecular Therapy-Methods & Clinical Development."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0520","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1124\/jpet.116.235952","article-title":"Reveglucosidase alfa (BMN 701), an IGF2-tagged rhAcid \u03b1-glucosidase, improves respiratory functional parameters in a murine model of Pompe disease","volume":"360","author":"Peng","year":"2017","journal-title":"Journal of Pharmacology and Experimental Therapeutics."},{"key":"10.1016\/j.ymgme.2024.108590_bb0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-017-0693-2","article-title":"A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease","volume":"12","author":"Byrne","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2024.108590_bb0530","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.1016\/j.nmd.2015.06.022","article-title":"PGM1 deficiency\u2013a heterogeneous myopathy with opportunities for treatment","volume":"25","author":"Voermans","year":"2015","journal-title":"Neuromuscul. Disord."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108590_bb0535","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1038\/s41467-023-40681-4","article-title":"CD98hc is a target for brain delivery of biotherapeutics","volume":"14","author":"Chew","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymgme.2024.108590_bb0540","first-page":"3","article-title":"Antisense oligonucleotide-mediated suppression of muscle glycogen synthase 1 synthesis as an approach for substrate reduction therapy of Pompe disease","author":"Clayton","year":"2014","journal-title":"Mol. Ther.\u2013Nucleic Acids"},{"key":"10.1016\/j.ymgme.2024.108590_bb0545","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1651-2227.2008.00656.x","article-title":"Substrate reduction therapy","volume":"97","author":"Platt","year":"2008","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2024.108590_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgmr.2022.100862","article-title":"Understanding and modifying Fabry disease: rationale and Design of a Pivotal Phase 3 study and results from a patient-reported outcome validation study","volume":"31","author":"Wanner","year":"2022","journal-title":"Molecular Genetics and Metabolism Reports."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.11.002","article-title":"Venglustat, an orally administered glucosylceramide synthase inhibitor: assessment over 3 years in adult males with classic fabry disease in an open-label phase 2 study and its extension study","volume":"138","author":"Deegan","year":"2023","journal-title":"Mol. Genet. Metab."},{"issue":"17","key":"10.1016\/j.ymgme.2024.108590_bb0560","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.3390\/jcm11175158","article-title":"Switching between enzyme replacement therapies and substrate reduction therapies in patients with Gaucher disease: data from the Gaucher outcome survey (GOS)","volume":"11","author":"Hughes","year":"2022","journal-title":"J. Clin. Med."},{"issue":"36","key":"10.1016\/j.ymgme.2024.108590_bb0565","doi-asserted-by":"crossref","first-page":"16909","DOI":"10.1016\/S0021-9258(19)75975-4","article-title":"Liver isozyme of rabbit glycogen synthase. Amino acid sequences surrounding phosphorylation sites recognized by cyclic AMP-dependent protein kinase","volume":"261","author":"Wang","year":"1986","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0570","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1006\/abbi.1994.1260","article-title":"Primary structure of human liver glycogen synthase deduced by cDNA cloning","volume":"311","author":"Nuttall","year":"1994","journal-title":"Arch. Biochem. Biophys."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108590_bb0575","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1073\/pnas.86.5.1443","article-title":"Human muscle glycogen synthase cDNA sequence: a negatively charged protein with an asymmetric charge distribution","volume":"86","author":"Browner","year":"1989","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108590_bb0580","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ymgme.2010.05.001","article-title":"Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease","volume":"100","author":"Ashe","year":"2010","journal-title":"Mol. Genet. Metab."},{"issue":"730","key":"10.1016\/j.ymgme.2024.108590_bb0585","doi-asserted-by":"crossref","first-page":"eadf1691","DOI":"10.1126\/scitranslmed.adf1691","article-title":"Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders","volume":"16","author":"Ullman","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymgme.2024.108590_bb0590","series-title":"Genetic Reduction of Muscle Glycogen is Well Tolerated in UK Biobank Participants. [Poster]. presented at: WORLD Symposium","author":"Homburger","year":"2022"},{"issue":"1","key":"10.1016\/j.ymgme.2024.108590_bb0595","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050027","article-title":"A prevalent variant in PPP1R3A impairs glycogen synthesis and reduces muscle glycogen content in humans and mice","volume":"5","author":"Savage","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.ymgme.2024.108590_bb0600","series-title":"Muscle Glycogen Reduction in Healthy Adults Treated with MZE001, an Oral Inhibitor of GYS1 and Potential Substrate Reduction Therapy for Pompe Disease. [Presentation]. presented at: WORLD Symposium","author":"Ullman","year":"2023"},{"key":"10.1016\/j.ymgme.2024.108590_bb0605","series-title":"Results from a First in Human Study of MZE001, an Orally Bioavailable Inhibitor of Glycogen Synthase 1 and Potential Substrate Reduction Therapy for Pompe Disease. [Presentation]. presented at: WORLD Symposium","author":"Ullman","year":"2023"},{"key":"10.1016\/j.ymgme.2024.108590_bb0610","series-title":"Substrate Reduction Therapy for Pompe Disease: Small Molecule Inhibition of Glycogen Synthase 1 in Preclinical Models [Presentation]. presented at: WORLD Symposium","author":"Ullman","year":"2023"},{"key":"10.1016\/j.ymgme.2024.108590_bb0615","series-title":"In Vitro Characterization of MZE001, an Orally Active GYS1 Inhibitor to Treat Pompe Disease. [Presentation]. Presented at: WORLD Symposium","author":"Choy","year":"2022"},{"key":"10.1016\/j.ymgme.2024.108590_bb0620","series-title":"Small Molecule Inhibition of Glycogen Synthase I Restores Autophagolysosomal and Metabolic Pathway Dysfunction in a Mouse Model of Pompe Disease. [Presentation]. presented at: WORLD Symposium","author":"Xi","year":"2023"},{"key":"10.1016\/j.ymgme.2024.108590_bb0625","series-title":"Centyrin-Targeted siRNA Conjugates Demonstrate Potential New Therapeutic Approach for Reduction of Skeletal Muscle Glycogen in Pompe Disease","author":"Aro Biotherapeutics","year":"2022"},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107994","article-title":"A novel siRNA targeting and delivery platform inhibits glycogen synthesis and reduces glycogen levels in skeletal and cardiac muscle in a mouse model of Pompe disease","volume":"141","author":"Pederson","year":"2024","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107977","article-title":"Nonclinical studies in non-human primates on ABX1100: a centyrin:Gys1 siRNA conjugate for the treatment of Pompe disease","volume":"141","author":"Nadler","year":"2024","journal-title":"Mol. Genet. Metab."},{"issue":"7","key":"10.1016\/j.ymgme.2024.108590_bb0640","first-page":"2296","article-title":"Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement","volume":"110","author":"Elstein","year":"2007","journal-title":"Blood, The Journal of the American Society of Hematology."},{"issue":"9214","key":"10.1016\/j.ymgme.2024.108590_bb0645","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher\u2019s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2024.108590_bb0650","author":"I Actelion Pharmaceuticals US"},{"issue":"9","key":"10.1016\/j.ymgme.2024.108590_bb0655","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/ajh.26276","article-title":"Clinical outcomes after 4.5years of eliglustat therapy for Gaucher disease type 1: phase 3 ENGAGE trial final results","volume":"96","author":"Mistry","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2024.108590_bb0660","author":"Genzyme Corporation"},{"issue":"1","key":"10.1016\/j.ymgme.2024.108590_bb0665","doi-asserted-by":"crossref","first-page":"20945","DOI":"10.1038\/s41598-021-00404-5","article-title":"Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model","volume":"11","author":"Viel","year":"2021","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0670","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/brain\/awac379","article-title":"Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial","volume":"146","author":"Schiffmann","year":"2023","journal-title":"Brain"},{"issue":"13","key":"10.1016\/j.ymgme.2024.108590_bb0675","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/atm.2019.05.02","article-title":"Liver depot gene therapy for Pompe disease","volume":"7","author":"Kishnani","year":"2019","journal-title":"Ann Transl Med."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108590_bb0680","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ymthe.2005.04.024","article-title":"Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II","volume":"12","author":"Franco","year":"2005","journal-title":"Mol. Ther."},{"issue":"13","key":"10.1016\/j.ymgme.2024.108590_bb0685","doi-asserted-by":"crossref","first-page":"287","DOI":"10.21037\/atm.2019.04.67","article-title":"Progress and challenges of gene therapy for Pompe disease","volume":"7","author":"Ronzitti","year":"2019","journal-title":"Ann Transl Med."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0690","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020302","article-title":"Gene therapy developments for Pompe disease","volume":"10","author":"Unnisa","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.ymgme.2024.108590_bb0695","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/JND-190426","article-title":"Advancements in AAV-mediated gene therapy for Pompe disease","volume":"7","author":"Salabarria","year":"2020","journal-title":"J Neuromuscul Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108590_bb0700","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1089\/humc.2017.146","article-title":"Safety of intradiaphragmatic delivery of adeno-associated virus-mediated alpha-glucosidase (rAAV1-CMV-hGAA) gene therapy in children affected by Pompe disease","volume":"28","author":"Corti","year":"2017","journal-title":"Hum. Gene. Ther. Clin. Dev."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108590_bb0705","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1089\/hum.2012.250","article-title":"Phase I\/II trial of adeno-associated virus\u2013mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in pompe disease: initial safety and ventilatory outcomes","volume":"24","author":"Smith","year":"2013","journal-title":"Hum. Gene Ther."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108590_bb0710","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/humc.2014.2514","article-title":"Phase I\/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV-GAA) gene vector in patients with Pompe disease","volume":"25","author":"Byrne","year":"2014","journal-title":"Hum. Gene. Ther. Clin. Dev."},{"issue":"Pt 2","key":"10.1016\/j.ymgme.2024.108590_bb0715","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.expneurol.2016.07.013","article-title":"Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: clinical evidence of respiratory plasticity","volume":"287","author":"Smith","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymgme.2024.108590_bb0720","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.ymgme.2024.108590_bb0725","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.ymgme.2024.108590_bb0730","author":"ClinicalTrials.gov"},{"issue":"418","key":"10.1016\/j.ymgme.2024.108590_bb0735","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam6375","article-title":"Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid \u03b1-glucosidase","volume":"9","author":"Puzzo","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymgme.2024.108590_bb0740","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2016.12.010","article-title":"Low-dose liver-targeted gene therapy for Pompe disease enhances therapeutic efficacy of ERT via immune tolerance induction","volume":"4","author":"Han","year":"2017","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108590_bb0745","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1038\/s41467-021-26744-4","article-title":"Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human Primates","volume":"12","author":"Costa-Verdera","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymgme.2024.108590_bb0750","first-page":"14","article-title":"Muscle-directed gene therapy corrects Pompe disease and uncovers species-specific GAA immunogenicity","volume":"12\/01","author":"Eggers","year":"2021","journal-title":"EMBO Mol. Med."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108590_bb0755","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/522236","article-title":"Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance","volume":"81","author":"Sun","year":"2007","journal-title":"Am. J. Hum. Genet."},{"issue":"7","key":"10.1016\/j.ymgme.2024.108590_bb0760","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/mt.2011.33","article-title":"Nonredundant roles of IL-10 and TGF-\u03b2 in suppression of immune responses to hepatic AAV-factor IX gene transfer","volume":"19","author":"Hoffman","year":"2011","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0765","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/mt.2009.195","article-title":"Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine Pompe disease","volume":"18","author":"Sun","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2024.108590_bb0770","author":"ClinicalTrials.gov"},{"issue":"7","key":"10.1016\/j.ymgme.2024.108590_bb0775","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.ymthe.2023.02.014","article-title":"Phase I study of liver depot gene therapy in late-onset Pompe disease","volume":"31","author":"Smith","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2024.108590_bb0780","author":"ClinicalTrials.gov"},{"issue":"13","key":"10.1016\/j.ymgme.2024.108590_bb0785","doi-asserted-by":"crossref","first-page":"290","DOI":"10.21037\/atm.2019.05.56","article-title":"Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy","volume":"7","author":"Byrne","year":"2019","journal-title":"Ann Transl Med."},{"key":"10.1016\/j.ymgme.2024.108590_bb0790","author":"Astellas"},{"key":"10.1016\/j.ymgme.2024.108590_bb0795","author":"Astellas"},{"key":"10.1016\/j.ymgme.2024.108590_bb0800","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.ymgme.2024.108590_bb0805","article-title":"First-in-human case report: AAV9-hGAA gene therapy for a patient with infantile-onset pompe disease","author":"Xiuwei","year":"2022","journal-title":"medRxiv"},{"issue":"5 Pt 1","key":"10.1016\/j.ymgme.2024.108590_bb0810","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1006\/mthe.2002.0580","article-title":"Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors","volume":"5","author":"Fraites","year":"2002","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.ymgme.2024.108590_bb0815","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1242\/dev.01169","article-title":"Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease","volume":"131","author":"Rucker","year":"2004","journal-title":"Development"},{"issue":"4","key":"10.1016\/j.ymgme.2024.108590_bb0820","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/mt.2013.282","article-title":"Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in Pompe mice","volume":"22","author":"Elmallah","year":"2014","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0825","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ana.24433","article-title":"Correcting neuromuscular deficits with gene therapy in Pompe disease","volume":"78","author":"Todd","year":"2015","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108590_bb0830","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.mt.6300100","article-title":"Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors","volume":"15","author":"Mah","year":"2007","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108590_bb0835","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/mt.2009.305","article-title":"Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease","volume":"18","author":"Mah","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2024.108590_bb0840","author":"Astellas"},{"issue":"2","key":"10.1016\/j.ymgme.2024.108590_bb0845","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3233\/JND-230122","article-title":"Real-world outcomes in patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy: findings from the RESTORE registry","volume":"11","author":"Servais","year":"2024","journal-title":"J Neuromuscul Dis."},{"key":"10.1016\/j.ymgme.2024.108590_bb0850","first-page":"3","article-title":"Targeted approaches to induce immune tolerance for Pompe disease therapy","author":"Doerfler","year":"2016","journal-title":"Molecular Therapy-Methods & Clinical Development."},{"issue":"8","key":"10.1016\/j.ymgme.2024.108590_bb0855","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41587-020-0642-9","article-title":"High-dose AAV gene therapy deaths","volume":"38","year":"2020","journal-title":"Nat. Biotechnol."}],"updated-by":[{"DOI":"10.1016\/j.ymgme.2025.109078","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000}}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224004748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224004748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T02:17:40Z","timestamp":1730859460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719224004748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":168,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1096719224004748"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108590","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pompe disease: Unmet needs and emerging therapies","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108590","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108590"}}